Search: id:"swepub:oai:DiVA.org:uu-16956" >
C-Peptide replaceme...
C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
- Article/chapterEnglish2007
Publisher, publication year, extent ...
-
American Diabetes Association,2007
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-16956
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-16956URI
-
https://doi.org/10.2337/dc06-1274DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:13911836URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-39412URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVE - C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS - This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS - The age of the 139 patients who completed the protocol was 44.2 ± 0.6 (mean ± SE) years and their duration of diabetes was 30.6 ± 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 ± 0.08 SD below body height-corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide-treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide-treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 ± 0.1% at baseline) decreased slightly but similarly in C-peptide- and placebo-treated patients during the study. CONCLUSIONS - C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Brismar, TomKarolinska Institutet
(author)
-
Johansson, Bo-Lennart
(author)
-
Lindström, Per
(author)
-
Juntti-Berggren, LisaKarolinska Institutet
(author)
-
Norrby, Anders
(author)
-
Berne, ChristianUppsala universitet,Institutionen för medicinska vetenskaper,Endokrinologi, diabetes och metabolism(Swepub:uu)chber255
(author)
-
Arnqvist, Hans,1943-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Avdelningen för medicinsk cellbiologi,Endokrin- och magtarmmedicinska kliniken US(Swepub:liu)hanar64
(author)
-
Bolinder, JanKarolinska Institutet
(author)
-
Wahren, JohnKarolinska Institutet
(author)
-
Karolinska InstitutetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:Diabetes Care: American Diabetes Association30:1, s. 71-760149-59921935-5548
Internet link
Find in a library
To the university's database
- By the author/editor
-
Ekberg, Karin
-
Brismar, Tom
-
Johansson, Bo-Le ...
-
Lindström, Per
-
Juntti-Berggren, ...
-
Norrby, Anders
-
show more...
-
Berne, Christian
-
Arnqvist, Hans, ...
-
Bolinder, Jan
-
Wahren, John
-
show less...
- Articles in the publication
-
Diabetes Care
- By the university
-
Uppsala University
-
Karolinska Institutet
-
Linköping University